Under the Paperwork Reduction Act of 1990, no persons are required to respond to a collection of information unless

Application Number

Filling Date 2006-05-23

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			
Filing Date		2006-05-23	
First Named Inventor Delfo		rd Ian CHRISTMAS	
Art Unit			
Examiner Name			
Attamen Desket Numb		402702 246 44266D2UG	

				U.S	PATENTS	Remove	
Examiner Initial*	Cite No Patent Number		Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	6268327	B1	2001-07-31	Lu et al.	See column 1 lines 8-12, column 1 lines 65-66, column 11 lines 30-64 especially "Example formulations" tables 1 and 2, relevant to claims 1-7, 12, 13: column 5, line 20 —	
	2	5700768	A	1997-12-23	Lu	Cited in the application; column 3, lines 34-38; column 4, line 63 column 6, line 65; column 11, lines 7-9; claims 1-7, 10-12, 16, 20-28; examples 1-7	
	3	4904359	A	1990-02-27	Pancheri et al.	Claim 1; example XVII	
	4	5780405	A	1998-07-14	He et al.	Examples 1, 2; table 1	
	5	4456543	A	1984-06-26	Owens	Column 5, lines 41-47	
	6	4230605		1980-10-28	Connolly et al.	Cited in the application	
	7	4861518		1989-08-29	Morganson et al.	Cited in the application	
	8	5266088		1993-11-30	Sandusky et al.	Cited in the application	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) First Named Inventor Art Unit

Application Number		
iling Date		2006-05-23
irst Named Inventor Delfo		rd Ian CHRISTMAS
Art Unit		
Examiner Name		
Manager Davids North		400700 046 4406600110

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name or Patentee or Applicant R		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	20030078178	A1	2003-04-24				See paragraph 2 and especially example VI, relevant to claims 1, 2, 6, 8, 12, 13		
If you wisi	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto	n. Add	
				FOREIG	3N PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	nd Publication Name of Patentee or where Relevant		Passages or Relevant	т5	
	1	0221774	EP		А3	1987-05-13	The Procter & Gamble Company		See example XVII, relevant to claims 1, 2, 6, 8, 12	
	2	93/21299	wo		A1	1993-10-28	The Procter & Gamble Company		See examples I-IV, relevant to claims 1, 2, 6, 8, 12	
	3	98/56884	wo	A1 1998-12-17 The Procte Company		The Proofer & Gan Company	nble	See examples I-IV, relevant to claims 1, 2, 6, 7, 12		
	4	2314339	GB		A	1997-12-24	Procter & Gamble		Example XII	
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	buttor	Add	
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher. (iv) and/or country where publisher.						Тs		
	1	Copy of Combined Search and Examination Report from The Patent Office in Great Britain dated May 21, 2004 for application GB 0327414.9								

U.S.PATENT APPLICATION PUBLICATIONS

	Application Number			
NEODMATION DIOOLOGUEE	Filing Date		2006-05-23	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Delfo		rd Ian CHRISTMAS	
Not for submission under 37 CFR 1.99)	Art Unit			
Not for Submission under or or it 1.55y	Examiner Name			
	Attorney Docket Numb	er	102792-216-11366P3US	

		EXAMINER SIGNATURE	
If you wish	h to a	kd additional non-patent literature document citation information please click the Add button Add	
	3	Copy of Whitten Opinion of the International Searching Authority for application PCTI/G82004I04096	
	2	Copy of Infernational Search Report dated December 22, 2004 for application PCT/GB2004/004096	

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16e Knic Code of USETO Petert Documents at sever USETO COLV or MEPE 901.04. * Enter of this that issued the document, by the increase ock (MPC) Standard 51.3. * The propriets peter for countert, the orbidates or the year of the register to preced the serial runner of the patient document.

Incl of countert by the sportports symbols as indicated on the document under WIPO Standard 51.16 if possible. **Applicant is to place a check mark here if English languages translation is attacked.

Application Number Fing Date 2006-05-23 First Number Interest Page 14 Page 14

CERTIFICATION STATEMENT

I loude dec of	Of It 1.57 und	1.50 to make the	appropriate selection	inaj.	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(vic).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-05-23
Name/Print	Andrew N. Parfornak	Registration Number	32431

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.